Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis

[1]  H. Ogata,et al.  Mucosal concentrations of N‐acetyl‐5‐aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine , 2020, Journal of gastroenterology and hepatology.

[2]  M. Parkes,et al.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults , 2019, Gut.

[3]  S. Targan,et al.  Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. , 2019, The New England journal of medicine.

[4]  A. Huitema,et al.  Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review , 2019, Digestion.

[5]  O. Spigset,et al.  Mucosal 5‐aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis , 2019, Alimentary pharmacology & therapeutics.

[6]  Siddharth Singh,et al.  AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. , 2019, Gastroenterology.

[7]  S. Masuda,et al.  Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmesalamine in Japanese Patients with Ulcerative Colitis. , 2019, Biological & pharmaceutical bulletin.

[8]  H. Ogata,et al.  Efficacy of Therapeutic Intervention for Patients With an Ulcerative Colitis Mayo Endoscopic Score of 1. , 2018, Inflammatory bowel diseases.

[9]  A. Ananthakrishnan,et al.  ACG Clinical Guideline: Ulcerative Colitis in Adults. , 2019, The American journal of gastroenterology.

[10]  James A. Proudfoot,et al.  No Benefit of Concomitant 5‐Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials , 2018, The American Journal of Gastroenterology.

[11]  K. Sugano,et al.  Evidence-based clinical practice guidelines for inflammatory bowel disease , 2018, Journal of Gastroenterology.

[12]  J. Gisbert,et al.  European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease , 2018, Journal of Crohn's & colitis.

[13]  D. Hommes,et al.  Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial , 2017, The Lancet.

[14]  Siddharth Singh,et al.  Natural History of Adult Ulcerative Colitis in Population‐based Cohorts: A Systematic Review , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  T. Molnár,et al.  Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. , 2017, Journal of Crohn's & colitis.

[16]  H. Ogata,et al.  The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry , 2017, PloS one.

[17]  S. Vermeire,et al.  Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis , 2017, The New England journal of medicine.

[18]  望月 万里.  The ulcerative colitis endoscopic index of severity is useful to predict medium-to long-term prognosis in ulcerative colitis patients with clinical remission(審査報告) , 2017 .

[19]  T. Molnár,et al.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. , 2017, Journal of Crohn's & colitis.

[20]  H. Ogata,et al.  The Ulcerative Colitis Endoscopic Index of Severity is Useful to Predict Medium- to Long-Term Prognosis in Ulcerative Colitis Patients with Clinical Remission. , 2016, Journal of Crohn's & colitis.

[21]  T. Kanai,et al.  Recent trends and future directions for the medical treatment of ulcerative colitis , 2016, Clinical Journal of Gastroenterology.

[22]  R. Eliakim,et al.  Combination of Corticosteroids with 5-Aminosalicylic Acids Compared to Corticosteroids Alone for Hospitalized Patients with Active Ulcerative Colitis. , 2016, The Israel Medical Association journal : IMAJ.

[23]  B. Feagan,et al.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2016, The Cochrane database of systematic reviews.

[24]  D. Rubin,et al.  Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial , 2016, Journal of Crohn's & colitis.

[25]  A. Cocco,et al.  A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[26]  Steven J Brown,et al.  Crohn's disease management after intestinal resection: a randomised trial , 2015, The Lancet.

[27]  C. Brensinger,et al.  Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  W. Sandborn,et al.  P-145 WELCOME 54-week Open-label Extension: Efficacy of Certolizumab Pegol in Crohn’s Disease Patients With Secondary Failure and Anti-Infliximab Antibodies , 2013 .

[29]  R. D'Incà,et al.  5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis. , 2013, World journal of gastroenterology.

[30]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[31]  B. Feagan,et al.  Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews , 2013, Inflammatory bowel diseases.

[32]  P. Rutgeerts,et al.  The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. , 2013, Gastroenterology.

[33]  S. Vermeire,et al.  Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management , 2012 .

[34]  N. Borruel,et al.  Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease , 2012, European journal of gastroenterology & hepatology.

[35]  P. Rutgeerts,et al.  Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. , 2011, Gastroenterology.

[36]  J. Belaiche,et al.  Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. , 2011, Journal of Crohn's & colitis.

[37]  P. Moayyedi,et al.  Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[38]  A. Vcev,et al.  Randomised clinical trial: a comparative dose‐finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis , 2011, Alimentary pharmacology & therapeutics.

[39]  T. Hibi,et al.  Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: A double-blind, randomized study , 2010, Inflammatory bowel diseases.

[40]  T. Hibi,et al.  Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: A double-blind, randomized study , 2010, Inflammatory bowel diseases.

[41]  A. Munakata,et al.  Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study , 2010, Journal of Gastroenterology.

[42]  J. Reguła,et al.  Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. , 2009, Gastroenterology.

[43]  R. D'Incà,et al.  W1213 Determination of 5-ASA and Its Derivatives in the Colonic Mucosa of Ulcerative Colitis Patients: A Surrogate Marker of Oxidative Damage? , 2009 .

[44]  R. D'Incà,et al.  DETERMINATION OF 5-ASA AND ITS DERIVATIVES IN THE COLONIC MUCOSA OF ULCERATIVE COLITIS PATIENTS: A SURROGATE MARKER OF OXIDATIVE DAMAGE? , 2009 .

[45]  M. Kamm,et al.  Effect of extended MMX mesalamine therapy for acute, mild‐to‐moderate Ulcerative Colitis , 2009, Inflammatory bowel diseases.

[46]  M. Kamm,et al.  MMX mesalazine for the induction of remission of mild‐to‐moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations , 2008, Alimentary pharmacology & therapeutics.

[47]  M. Vatn,et al.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.

[48]  M. Kamm,et al.  Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. , 2007, Gastroenterology.

[49]  M. Kamm,et al.  Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[50]  S. Hanauer,et al.  Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. , 2007, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[51]  B. Feagan,et al.  Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. , 2016, The Cochrane database of systematic reviews.

[52]  O. Dewit,et al.  Once daily MMX mesalazine for the treatment of mild‐to‐moderate ulcerative colitis: a phase II, dose‐ranging study , 2006, Alimentary pharmacology & therapeutics.

[53]  A. Lavy,et al.  Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis , 2006, Alimentary pharmacology & therapeutics.

[54]  G. Lichtenstein.  Combined Oral and Enema Treatment With Pentasa (Mesalazine) Is Superior to Oral Therapy Alone in Patients With Extensive Mild/Moderate Active Ulcerative Colitis: A Randomised, Double Blind, Placebo Controlled Study , 2006 .

[55]  F. Ajayi,et al.  Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial , 2005, The American Journal of Gastroenterology.

[56]  P. Marteau,et al.  An unusual cause of soft tissue infection , 2005, Gut.

[57]  O. Paoluzi,et al.  Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1‐year follow‐up study , 2005, Alimentary pharmacology & therapeutics.

[58]  K. Petraki,et al.  A Prospective Randomized Observer-Blind 2-Year Trial of Azathioprine Monotherapy versus Azathioprine and Olsalazine for the Maintenance of Remission of Steroid-Dependent Ulcerative Colitis , 2004, American Journal of Gastroenterology.

[59]  M. Vieth,et al.  The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[60]  S. Campbell,et al.  Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy , 2001, European journal of gastroenterology & hepatology.

[61]  H. Ogata,et al.  Measurement of Colonic Mucosal Concentrations of 5-Aminosalicylic Acid Is Useful for Estimating Its Therapeutic Efficacy in Distal Ulcerative Colitis: Comparison of Orally Administered Mesalamine and Sulfasalazine , 2001, Inflammatory bowel diseases.

[62]  R. Giacomelli,et al.  Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis , 2000, Gut.

[63]  P. Fockens,et al.  Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis , 1995 .

[64]  P. Fockens,et al.  Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. , 1995, European journal of gastroenterology & hepatology.

[65]  S. Hanauer,et al.  Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. , 1993, The American journal of gastroenterology.

[66]  S. Lo,et al.  Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. , 1991, Annals of internal medicine.

[67]  M. De Vos,et al.  High-performance liquid chromatographic assay for the determination of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid concentrations in endoscopic intestinal biopsy in humans. , 1991, Journal of chromatography.

[68]  J. Rask-Madsen,et al.  Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. , 1990, Gut.

[69]  M. Peppercorn,et al.  A Double-Blind, Placebo Controlled, Multicentre Study of the Efficacy And Safety of 5-Aminosalicylic Acid Tablets in the Treatment of Ulcerative Colitis , 1990 .

[70]  S. Bondesen,et al.  Kinetics of 5-aminosalicylic acid after jejunal instillation in man. , 1983, British journal of clinical pharmacology.

[71]  M. Peppercorn,et al.  The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. , 1972, The Journal of pharmacology and experimental therapeutics.